Risk factors for and prediction of mortality in critically ill medical–surgical patients receiving heparin thromboprophylaxis

Annals of Intensive Care

Table 5 Exploratory analyses for model performance of Models 1 and 3 in different countries for 60-day hospital mortality using the whole dataset

Model performance	Goodness-of-fit		C index	SMR (95 % CI)
Model performance	p value^a	AIC	C index	SMR (95 % CI)
Model 1^b
Canada (n = 2456)	0.41	7639	0.61	0.981 (0.942–1.021)
Australia (n = 768)	0.11	1418	0.62	0.965 (0.897–1.037)
USA and UK (n = 109)	0.64	130	0.68	0.982 (0.804–1.186)
Saudi Arabia and Brazil (n = 413)	0.77	1713	0.55	1.155 (1.054–1.263)
Model 3^c
Canada (n = 2456)	0.88	7489	0.62	0.996 (0.956–1.037)
Australia (n = 768)	0.80	1349	0.63	0.968 (0.898–1.043)
USA and UK (n = 109)	0.41	125	0.71	0.981 (0.801–1.190)
Saudi Arabia and Brazil (n = 413)	0.25	1660	0.63	1.099 (0.943–1.311)

AIC Akaike information criterion, SMR standardized mortality ratio
^aBased on Groennesby and Borgan test
^bModel 1 included APACHE II score only
^cModel 3 consisted of BMI, medical admission, inotropes or vasopressors, acetylsalicylic acid or clopidogrel, APACHE II score and the interaction between BMI and APACHE II score